(1)Li X, Wu W, Tao J, Guo X. Integrated analysis of single-cell and bulk transcriptomics reveals the prognostic value and underlying mechanisms of crotonylation in ovarian cancer. Front Immunol. 2025 Sep 10;16:1596080.
(2) Lu Y#, Zhang Y#, Li W, Jiang H, Wang J, Guo X*. Tumor Cell-Expressed Herpesvirus Entry Mediator Regulates Proliferation and Adaptive Immunity in Ovarian Cancer. Immun Inflamm Dis. 2025 Mar;13(3):e70175. doi: 10.1002/iid3.70175.
(3) Jiang H#, Awuti G, Guo X*. Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer. ACS Omega. 2023 Aug 30;8(36):33017-33031.
(4) Zhang X#, Wang J, Liu N, Wu W, Li H, Lu W*, Guo X*. Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer In Vivo and Reverse Cisplatin Resistance. Mol Pharm. 2023 Nov 6;20(11):5440-5453.
(5) Chu Y#, Jin X, Guo X*. MCM2 promotes the stemness of endometrial cancer cells via the Akt/β-catenin pathway. Neoplasma. 2023 Oct;70(5):610-620.
(6) Yang M#, Hu H#, Wu S#, Ding J, Yin B, Huang B, Li F, Guo X*, Han L*. EIF4A3-regulated circ_0087429 can reverse EMT and inhibit the progression of cervical cancer via miR-5003-3p-dependent upregulation of OGN expression. J Exp Clin Cancer Res. 2022, 41(1):165.
(7) Gao F#, Ma X, Xu Y, Fu L, Guo X*. Management of Acquired Uterine Arteriovenous Malformations Associated with Retained Products of Conception. J Vasc Interv Radio.l 2022, 33(5):547-553.
(8)Sun J, Li L, Chen H, Gan L, Guo X*, Sun J*: Identification and Validation of an m7G-Related lncRNAs Signature for Prognostic Prediction and Immune Function Analysis in Endometrial Cancer. Genes (Basel) 2022, 13(8).
